Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rosuvastatin/choline fenofibrate

Drug Profile

Rosuvastatin/choline fenofibrate

Alternative Names: ABT-143; ABT-335/rosuvastatin; Certriad; choline-fenofibrate/rosuvastatin; Rosuvastatin/ABT-335; Rosuvastatin/fenofibric acid delayed release

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories; AstraZeneca
  • Class Antihyperlipidaemics; Fibric acid derivatives; Fluorobenzenes; Propionates; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action HMG-CoA reductase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hyperlipidaemia

Most Recent Events

  • 22 Dec 2010 Discontinued - Preregistration for Hyperlipidaemia in USA (PO)
  • 30 Mar 2010 AstraZeneca & Abbott receive complete response letter from the FDA for rosuvastatin/choline fenofibrate in Hyperlipidaemia
  • 19 Jun 2009 Post-hoc efficacy data from two phase III trials in Dyslipidaemia presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top